Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.
about
Structural and functional studies on platelet-derived growth factorExpression cDNA cloning of a transforming gene encoding the wild-type G alpha 12 gene productSuramin inhibits initiation of defense signaling by systemin, chitosan, and a beta-glucan elicitor in suspension-cultured Lycopersicon peruvianum cellsStructural and functional aspects of platelet-derived growth factorSuramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.Suramin in adrenocortical cancer: limited efficacy and serious toxicity.Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: reversal by suramin.The effect of suramin on healing adult rodent dermal woundsSuramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin.RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.Nomenclature and classification of purinoceptors.Delivery of platelet-derived growth factor as a chemotactic factor for mesenchymal stem cells by bone-mimetic electrospun scaffolds.Steroid hormone agonists and antagonists in the treatment of cancer.Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells.Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation.Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cellsSafety of recombinant human platelet-derived growth factor-BB in Augment(®) Bone GraftAutocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surfaceTransformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.The v-sis oncoprotein loses transforming activity when targeted to the early Golgi complexStimulation of beta1 integrins on fibroblasts induces PDGF independent tyrosine phosphorylation of PDGF beta-receptors.Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transductionSpecific activation of p85-p110 phosphatidylinositol 3'-kinase stimulates DNA synthesis by ras- and p70 S6 kinase-dependent pathways.Differentiation induction of mouse embryonic stem cells into sinus node-like cells by suramin.Secreted int-1 protein is associated with the cell surfaceInducible overexpression and secretion of int-1 protein.Expression of recombinant platelet-derived growth factor A- and B-chain homodimers in rat-1 cells and human fibroblasts reveals differences in protein processing and autocrine effects.A colony-stimulating factor 1 (CSF-1) receptor/platelet-derived growth factor-beta receptor gene fusion confers CSF-1 independence and tumorigenicity on a c-myc-immortalized monocyte cell lineDominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cellsSuramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cellsLysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway.Platelet-derived growth factor: mechanism of action and possible in vivo function.Cytokines of the lung.Autocrine PDGF stimulation in malignancies.The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis.Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.The level of intracellular glutathione is a key regulator for the induction of stress-activated signal transduction pathways including Jun N-terminal protein kinases and p38 kinase by alkylating agents
P2860
Q24555662-27C1B1CC-5FE3-403F-AD03-9E3BB38A5197Q24611116-9E0A7F62-F194-425E-B8A4-5EFB066A8291Q28142406-DC8038A9-1D01-43A3-9D59-1EF9D68487C3Q28645857-6D235F40-397E-46E9-8554-F9556F42E2F6Q30449312-608A88E9-E36B-4A29-970C-66DE5671897CQ33491133-359A1B37-538F-4ADE-B208-CCEEDB1D5769Q33687824-77D9DCB6-0BCD-4C99-AB2D-0D998685796EQ33880834-707BED5B-2A00-4AD7-B9D5-BFBEEA526EA6Q33906984-83813E65-D8FF-4C80-B387-B29217FFA562Q34127133-3EC8A0DE-DDBF-48E3-9970-835790DD784FQ34308033-F815B977-40C2-4D72-B07C-F9831EFC6B55Q34313642-ED55F966-9DE9-47B5-B834-616278A496D0Q34324355-AF500DCF-FA9D-406C-87B8-723076FF2A3DQ34342438-7A925F82-8B16-498B-8544-22C0A422CD2CQ35309303-2FFC7BFE-B4A8-4FA2-8837-8D844397F62DQ35600805-687DF2C8-80C4-49A7-8C97-BE685A94F281Q35688302-6B66312B-A245-4CA4-B270-DABBC4C3DBFAQ35763823-E8E290B7-FDCD-4A67-87A4-0A6ADB6CE148Q35884670-A4195785-1FC0-4B38-91DD-7C7F04D93D88Q36219059-2C33EA81-05A7-4CD7-A6BB-07C9929F0692Q36221812-4094A034-D69C-452C-B327-5135268B00C3Q36234954-FA0F68E4-EBAA-447B-8524-25C1DACBE2EFQ36382363-1A70D4B7-9568-4878-A842-16683F284546Q36531805-4858ECE0-2BA9-4229-B91A-D2F00A779C4EQ36564768-5F36096F-A784-40B8-901D-A551E5D69D58Q36572956-DFFC2F5D-702F-4973-8238-A6C24039A72AQ36710372-31D712BF-FF84-4E20-B6AB-70ECFF1216F1Q36758870-9E849544-4C2C-41DF-AF1D-4FDC3C526698Q36791505-CB7D71A1-70D7-4106-91EB-E133846E6672Q36809489-D32CEA40-1499-4CB8-B108-227131D65130Q36826672-1624318E-B1D8-4E42-B5C7-F118CCCC26CEQ36934032-3A6580DF-49EC-4EA1-BA74-BBB7F3352A96Q37384485-D5F4A57E-4871-4BBD-8774-ECD4A2EEAF22Q37565963-5FEF7F0B-99CD-4A7A-9CEE-D0B84AF8B1D1Q37873667-05346E25-8018-425D-8BAF-61AE5F1E2DFBQ38003387-F3BD99F0-CD3D-4BE9-85BB-7B376761B273Q38003528-7585AA42-136E-4342-AA7A-1886EE1B1B43Q39444400-1214AA97-7D74-447F-B436-9AA7C7FE9313Q39458674-17CA5D13-03B8-4224-AD0D-C2A0CD4300FBQ40023085-A930D735-F178-4748-B948-550E2221C08A
P2860
Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@en
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@nl
type
label
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@en
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@nl
prefLabel
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@en
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@nl
P2860
P356
P1476
Efficient reversion of simian ...... nduced mitogenesis by suramin.
@en
P2093
P2860
P304
P356
10.1073/PNAS.83.17.6440
P407
P577
1986-09-01T00:00:00Z